Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO®
TEPMETKO is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harboring alterations leading to METex14 skipping Not intended
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million Darmstadt, Germany, December 8, 2021 – Merck, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of € 600 mil.
Phase II post-hoc data show evobrutinib reduced acute and chronic inflammation processes in the central nervous system that may be early indicators of MS disease progression Additional data
New data presented at ECTRIMS 2021 highlight improvement in measures of physical and mental health of patients with relapsing multiple sclerosis (RMS) after one year of treatment with MAVENCLAD